Kornblau SM - Search Results

1

VEGFC Antibody Therapy Drives Differentiation of AML.

Kampen KR, Scherpen FJG, Mahmud H, Ter Elst A, Mulder AB, Guryev V, Verhagen HJMP, De Keersmaecker K, Smit L, Kornblau SM, De Bont ESJM. Kampen KR, et al. Among authors: kornblau sm. Cancer Res. 2018 Oct 15;78(20):5940-5948. doi: 10.1158/0008-5472.CAN-18-0250. Epub 2018 Sep 5. Cancer Res. 2018. PMID: 30185550

2

Clinical implications of decreased retinoblastoma protein expression in acute myelogenous leukemia.

Kornblau SM, Xu HJ, del Giglio A, Hu SX, Zhang W, Calvert L, Beran M, Estey E, Andreeff M, Trujillo J, et al. Kornblau SM, et al. Cancer Res. 1992 Sep 1;52(17):4587-90. Cancer Res. 1992. PMID: 1511426

3

Low and maximally phosphorylated levels of the retinoblastoma protein confer poor prognosis in newly diagnosed acute myelogenous leukemia: a prospective study.

Kornblau SM, Andreeff M, Hu SX, Xu HJ, Patel S, Theriault A, Koller C, Kantarjian H, Estey E, Deisseroth AB, Benedict WF. Kornblau SM, et al. Clin Cancer Res. 1998 Aug;4(8):1955-63. Clin Cancer Res. 1998. PMID: 9717825

4

High levels of constitutive WAF1/Cip1 protein are associated with chemoresistance in acute myelogenous leukemia.

Zhang W, Kornblau SM, Kobayashi T, Gambel A, Claxton D, Deisseroth AB. Zhang W, et al. Among authors: kornblau sm. Clin Cancer Res. 1995 Sep;1(9):1051-7. Clin Cancer Res. 1995. PMID: 9816079

5

The prognostic impact of BCL2 protein expression in acute myelogenous leukemia varies with cytogenetics.

Kornblau SM, Thall PF, Estrov Z, Walterscheid M, Patel S, Theriault A, Keating MJ, Kantarjian H, Estey E, Andreeff M. Kornblau SM, et al. Clin Cancer Res. 1999 Jul;5(7):1758-66. Clin Cancer Res. 1999. PMID: 10430080

6

BAX and PKCalpha modulate the prognostic impact of BCL2 expression in acute myelogenous leukemia.

Kornblau SM, Vu HT, Ruvolo P, Estrov Z, O'Brien S, Cortes J, Kantarjian H, Andreeff M, May WS. Kornblau SM, et al. Clin Cancer Res. 2000 Apr;6(4):1401-9. Clin Cancer Res. 2000. PMID: 10778970

7

The prognostic significance of p16(INK4a)/p14(ARF) locus deletion and MDM-2 protein expression in adult acute myelogenous leukemia.

Faderl S, Kantarjian HM, Estey E, Manshouri T, Chan CY, Rahman Elsaied A, Kornblau SM, Cortes J, Thomas DA, Pierce S, Keating MJ, Estrov Z, Albitar M. Faderl S, et al. Among authors: kornblau sm. Cancer. 2000 Nov 1;89(9):1976-82. doi: 10.1002/1097-0142(20001101)89:9<1976::aid-cncr14>3.3.co;2-e. Cancer. 2000. PMID: 11064355

8

Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation.

Giles FJ, Kantarjian HM, Kornblau SM, Thomas DA, Garcia-Manero G, Waddelow TA, David CL, Phan AT, Colburn DE, Rashid A, Estey EH. Giles FJ, et al. Among authors: kornblau sm. Cancer. 2001 Jul 15;92(2):406-13. doi: 10.1002/1097-0142(20010715)92:2<406::aid-cncr1336>3.0.co;2-u. Cancer. 2001. PMID: 11466696

9

Sudden onset of the blastic phase of chronic myelogenous leukemia: patterns and implications.

Kantarjian H, O'Brien S, Cortes J, Giles F, Thomas D, Kornblau S, Shan J, Beth Rios M, Keating M, Freireich E, Talpaz M. Kantarjian H, et al. Cancer. 2003 Jul 1;98(1):81-5. doi: 10.1002/cncr.11477. Cancer. 2003. PMID: 12833459 Free article.

10

Simultaneous inhibition of PDK1/AKT and Fms-like tyrosine kinase 3 signaling by a small-molecule KP372-1 induces mitochondrial dysfunction and apoptosis in acute myelogenous leukemia.

Zeng Z, Samudio IJ, Zhang W, Estrov Z, Pelicano H, Harris D, Frolova O, Hail N Jr, Chen W, Kornblau SM, Huang P, Lu Y, Mills GB, Andreeff M, Konopleva M. Zeng Z, et al. Among authors: kornblau sm. Cancer Res. 2006 Apr 1;66(7):3737-46. doi: 10.1158/0008-5472.CAN-05-1278. Cancer Res. 2006. PMID: 16585200

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

347 results

Search Page